It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MLYS’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MLYS’s TA Score shows that 5 TA indicator(s) are bullish while MNKD’s TA Score has 4 bullish TA indicator(s).
MLYS (@Biotechnology) experienced а +6.71% price change this week, while MNKD (@Biotechnology) price change was +1.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.83%. For the same industry, the average monthly price growth was +1.96%, and the average quarterly price growth was +1945.11%.
MLYS is expected to report earnings on Aug 18, 2026.
MNKD is expected to report earnings on Aug 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| MLYS | MNKD | MLYS / MNKD | |
| Capitalization | 2.26B | 1.21B | 186% |
| EBITDA | -171.45M | 27.6M | -621% |
| Gain YTD | -29.457 | -30.864 | 95% |
| P/E Ratio | N/A | 143.00 | - |
| Revenue | 0 | 361M | - |
| Total Cash | 646M | 134M | 482% |
| Total Debt | N/A | 331M | - |
MNKD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 42 | |
P/E GROWTH RATING 1..100 | 5 | |
SEASONALITY SCORE 1..100 | 34 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| MLYS | MNKD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 73% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 78% |
| Advances ODDS (%) | 1 day ago 85% | 6 days ago 79% |
| Declines ODDS (%) | 16 days ago 86% | 16 days ago 80% |
| BollingerBands ODDS (%) | N/A | 1 day ago 73% |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 79% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| HNCTX | 25.96 | N/A | N/A |
| Hartford International Growth R5 | |||
| KAUFX | 6.22 | N/A | N/A |
| Federated Hermes Kaufmann R | |||
| JGYAX | 14.48 | N/A | N/A |
| JHancock Global Shareholder Yield A | |||
| GSMVX | 20.31 | N/A | N/A |
| Goldman Sachs Small/Mid Cap Equity Instl | |||
| CWMEX | 64.68 | -0.18 | -0.28% |
| American Funds Washington Mutual 529E | |||
A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with IONS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then IONS could also see price increases.
| Ticker / NAME | Correlation To MLYS | 1D Price Change % | ||
|---|---|---|---|---|
| MLYS | 100% | +0.91% | ||
| IONS - MLYS | 64% Loosely correlated | +0.13% | ||
| CYTK - MLYS | 58% Loosely correlated | +1.06% | ||
| VCYT - MLYS | 33% Loosely correlated | +1.13% | ||
| MNKD - MLYS | 33% Poorly correlated | +0.77% | ||
| SANA - MLYS | 32% Poorly correlated | -0.30% | ||
More | ||||
A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with IONS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then IONS could also see price increases.
| Ticker / NAME | Correlation To MNKD | 1D Price Change % | ||
|---|---|---|---|---|
| MNKD | 100% | +0.77% | ||
| IONS - MNKD | 47% Loosely correlated | +0.13% | ||
| VCYT - MNKD | 44% Loosely correlated | +1.13% | ||
| CYTK - MNKD | 40% Loosely correlated | +1.06% | ||
| UTHR - MNKD | 37% Loosely correlated | +1.16% | ||
| AMRN - MNKD | 36% Loosely correlated | +1.52% | ||
More | ||||